Achilles Therapeutics Future Growth
Future criteria checks 0/6
Achilles Therapeutics's earnings are forecast to decline at 3.9% per annum. EPS is expected to decline by 1% per annum.
Key information
-3.9%
Earnings growth rate
-1.0%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -52 | -92 | N/A | 1 |
| 12/31/2025 | N/A | -36 | -68 | N/A | 1 |
| 12/31/2024 | N/A | -64 | -59 | N/A | 1 |
| 9/30/2024 | N/A | -67 | -64 | -63 | N/A |
| 6/30/2024 | N/A | -64 | -49 | -48 | N/A |
| 3/31/2024 | N/A | -64 | -49 | -48 | N/A |
| 12/31/2023 | N/A | -70 | -50 | -48 | N/A |
| 9/30/2023 | N/A | -75 | -57 | -54 | N/A |
| 6/30/2023 | N/A | -71 | -63 | -58 | N/A |
| 3/31/2023 | N/A | -71 | -63 | -57 | N/A |
| 12/31/2022 | N/A | -71 | -67 | -60 | N/A |
| 9/30/2022 | N/A | -65 | -62 | -54 | N/A |
| 6/30/2022 | N/A | -66 | -67 | -60 | N/A |
| 3/31/2022 | N/A | -65 | -70 | -63 | N/A |
| 12/31/2021 | N/A | -61 | -67 | -59 | N/A |
| 9/30/2021 | N/A | -56 | -65 | -53 | N/A |
| 6/30/2021 | N/A | -51 | -66 | -51 | N/A |
| 3/31/2021 | N/A | -42 | -50 | -36 | N/A |
| 12/31/2020 | N/A | -33 | -37 | -25 | N/A |
| 9/30/2020 | N/A | -25 | -29 | -22 | N/A |
| 6/30/2020 | N/A | -19 | -21 | -19 | N/A |
| 3/31/2020 | N/A | -16 | -20 | -18 | N/A |
| 12/31/2019 | N/A | -14 | -15 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 698 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 698 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 698 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 698's revenue is forecast to grow faster than the German market.
High Growth Revenue: 698 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 698's Return on Equity is forecast to be high in 3 years time